A Study to Evaluate YH001 in Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-12-08
Target enrollment:
Participant gender:
Summary
This is an open-label, dose-escalation study of the study drug YH001 . The study is designed
to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended Phase 2
dose (RP2D) of YH001 in subjects with advanced solid tumors.